Erin Miller, Marketing Director
FOR IMMEDIATE RELEASE
New Study Catalogues Evidence for Probiotic, Bacillus coagulans
Review paper supports multiple health claims for specific Bacillus coagulans strain, GanedenBC30
CLEVELAND, OH (January 25, 2011) – A new paper reviewing recent research and safety data published in the peer-reviewed journal IFIS (International Food Information Service) Food Science and Technology Bulletin provides scientific support for Ganeden’s patented probiotic strain of Bacillus coagulans. The overview supports the use of probiotics in general and a specific Bacillus coagulans strain, known as GanedenBC30 (Bacillus coagulans GBI-30, 6086) for its probiotic attributes. The study summarizes how GanedenBC30 supports its health claims related to safety, gastrointestinal health, immune health, joint health and includes never before published data.
“Probiotic strains have been traditionally limited to Lactobacillus and Bifidobacterium,” explained Dr. Glenn Gibson, one of the world’s leading probiotic experts, co-author of the paper and professor of microbiology at Reading University, England. “The evaluation of this recent data shows great promise for Bacillus coagulans as a new type of probiotic that’s come to the forefront.”
Probiotics, or “beneficial bacteria,” have been shown to support digestive health and immunity. The challenge for probiotics has always been survivability through harsh stomach acids in order to arrive in the intestines where they can have the greatest digestive health benefit. Bacillus coagulans based strains of probiotics have a distinct advantage since they are able to survive gastric acidity because they form a naturally occurring layer of organic material that helps protect the delicate genetic core of the probiotic. Conventional probiotics such as Lactobacillus and Bifidobacterium are unable to form this protective shield, making them more vulnerable.
“Bacillus coagulans behaves in totally different way than many common probiotics today due to its spore-forming nature,” Gibson commented. “This exciting development in probiotic technology could very well lead to seeing Bacillus coagulans probiotics like GanedenBC30 showing up in more products due to its hearty nature.”
Highlights of the research data review of GanedenBC30 include relieving abdominal pain and bloating in IBS sufferers, showing a potential to digest protein, lactose and fructose, positively affecting the immune system, protecting against two strains of influenza, decreasing joint pain and supporting mobility in rheumatoid arthritis sufferers and surviving through a simulated gastric environment. The safety data reviewed seven tests and revealed no safety issues even when GanedenBC30 was consumed in high quantities.
GanedenBC30 is the probiotic included in Digestive Advantage® and Sustenex® products which have already been demonstrated safe and effective. GanedenBC30 can also be found as an added ingredient in over 45 functional foods and beverages, including bread, nutrition bars, instant soup mix, hot tea, ice cream and frozen yogurt.
Ganeden is at the forefront of probiotic research and product development with an extensive library of published studies and more than 100 patents for probiotic technologies in the food, beverage, animal health, sports nutrition and personal care ingredients markets. Ganeden is best known for GanedenBC30 (Bacillus coagulans GBI-30, 6086), its patented, FDA GRAS, non-GMO, highly stable probiotic ingredient. Ganeden's newest ingredient, Bonicel, is the first science-backed, probiotic-derived, personal care ingredient shown to dramatically reduce signs of aging. For more information about Ganeden and licensing opportunities visit GanedenProbiotics.com.